|
1
|
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
|
Lancet
|
2006
|
10.91
|
|
2
|
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
|
N Engl J Med
|
2015
|
4.26
|
|
3
|
Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.
|
Lancet Infect Dis
|
2011
|
2.82
|
|
4
|
Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
|
Lancet Infect Dis
|
2013
|
2.51
|
|
5
|
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
|
Addiction
|
2008
|
1.76
|
|
6
|
Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon.
|
Antivir Ther
|
2013
|
1.68
|
|
7
|
Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
|
Clin Infect Dis
|
2009
|
1.65
|
|
8
|
Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study.
|
Antivir Ther
|
2003
|
1.55
|
|
9
|
Health-related quality of life after 1 year of highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2003
|
1.44
|
|
10
|
Financial barriers to HIV treatment in Yaoundé, Cameroon: first results of a national cross-sectional survey.
|
Bull World Health Organ
|
2009
|
1.42
|
|
11
|
Nonadherence among HIV-infected injecting drug users: the impact of social instability.
|
J Acquir Immune Defic Syndr
|
2002
|
1.41
|
|
12
|
Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
|
Antivir Ther
|
2005
|
1.40
|
|
13
|
Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.
|
J Antimicrob Chemother
|
2009
|
1.39
|
|
14
|
Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study.
|
HIV Clin Trials
|
2003
|
1.36
|
|
15
|
Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase.
|
J Acquir Immune Defic Syndr
|
2006
|
1.35
|
|
16
|
Decentralization of HIV care in Cameroon: increased access to antiretroviral treatment and associated persistent barriers.
|
Health Policy
|
2009
|
1.31
|
|
17
|
Access to and use of unauthorised online HIV self-tests by internet-using French-speaking men who have sex with men.
|
Sex Transm Infect
|
2012
|
1.29
|
|
18
|
Discrimination against HIV-infected people and the spread of HIV: some evidence from France.
|
PLoS One
|
2007
|
1.27
|
|
19
|
Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon (EVAL survey, ANRS 12-116).
|
Trop Med Int Health
|
2008
|
1.26
|
|
20
|
Unprotected sex in regular partnerships among homosexual men living with HIV: a comparison between sero-nonconcordant and seroconcordant couples (ANRS-EN12-VESPA Study).
|
AIDS
|
2007
|
1.24
|
|
21
|
Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003).
|
Drug Alcohol Depend
|
2006
|
1.21
|
|
22
|
Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon context: promoting the use of medication reminder methods.
|
J Acquir Immune Defic Syndr
|
2011
|
1.21
|
|
23
|
HIV disclosure and unsafe sex among HIV-infected women in Cameroon: results from the ANRS-EVAL study.
|
Soc Sci Med
|
2009
|
1.19
|
|
24
|
Finding a cure for HIV: will it ever be achievable?
|
J Int AIDS Soc
|
2011
|
1.18
|
|
25
|
Health related quality of life among both current and former injection drug users who are HIV-infected.
|
Drug Alcohol Depend
|
2006
|
1.18
|
|
26
|
Unsafe sex in regular partnerships among heterosexual persons living with HIV: evidence from a large representative sample of individuals attending outpatients services in France (ANRS-EN12-VESPA Study).
|
AIDS
|
2007
|
1.17
|
|
27
|
ANRS-COM'TEST: description of a community-based HIV testing intervention in non-medical settings for men who have sex with men.
|
BMJ Open
|
2012
|
1.16
|
|
28
|
Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research.
|
HIV Clin Trials
|
2007
|
1.14
|
|
29
|
Performance of HIV care decentralization from the patient's perspective: health-related quality of life and perceived quality of services in Cameroon.
|
Health Policy Plan
|
2011
|
1.12
|
|
30
|
Factors correlated with disclosure of HIV infection in the French Antilles and French Guiana: results from the ANRS-EN13-VESPA-DFA Study.
|
AIDS
|
2007
|
1.09
|
|
31
|
Prevalence of unsafe sex with one's steady partner either HIV-negative or of unknown HIV status and associated determinants in Cameroon (EVAL ANRS12-116 survey).
|
Sex Transm Infect
|
2009
|
1.08
|
|
32
|
Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study.
|
Antivir Ther
|
2008
|
1.06
|
|
33
|
Internet-using men who have sex with men would be interested in accessing authorised HIV self-tests available for purchase online.
|
AIDS Care
|
2012
|
1.06
|
|
34
|
Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study.
|
AIDS
|
2007
|
1.05
|
|
35
|
Health-related quality of life in French people living with HIV in 2003: results from the national ANRS-EN12-VESPA Study.
|
AIDS
|
2007
|
1.05
|
|
36
|
HIV prevalence and sexual risk behaviors associated with awareness of HIV status among men who have sex with men in Paris, France.
|
AIDS Behav
|
2013
|
1.02
|
|
37
|
Expanding access to non-medicalized community-based rapid testing to men who have sex with men: an urgent HIV prevention intervention (the ANRS-DRAG study).
|
PLoS One
|
2013
|
0.99
|
|
38
|
The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice.
|
Antivir Ther
|
2007
|
0.98
|
|
39
|
Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).
|
Int J Drug Policy
|
2007
|
0.98
|
|
40
|
Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.
|
Drug Alcohol Depend
|
2008
|
0.98
|
|
41
|
Delayed first consultation after diagnosis of HIV infection in Cameroon.
|
AIDS
|
2009
|
0.98
|
|
42
|
Drug injection cessation among HIV-infected injecting drug users.
|
Addict Behav
|
2004
|
0.98
|
|
43
|
Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
|
AIDS Care
|
2011
|
0.96
|
|
44
|
Higher risk of unsafe sex and impaired quality of life among patients not receiving antiretroviral therapy in Cameroon: results from the EVAL survey (ANRS 12-116).
|
AIDS
|
2010
|
0.95
|
|
45
|
Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south.
|
AIDS
|
2004
|
0.94
|
|
46
|
Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France.
|
Addict Behav
|
2008
|
0.94
|
|
47
|
Awareness of non-occupational HIV postexposure prophylaxis among French people living with HIV: the need for better targeting.
|
AIDS
|
2007
|
0.93
|
|
48
|
Empowering HIV testing as a prevention tool: targeting interventions for high-risk men who have sex with men.
|
AIDS Care
|
2012
|
0.92
|
|
49
|
Non-medical use of opioids among HIV-infected opioid dependent individuals on opioid maintenance treatment: the need for a more comprehensive approach.
|
Harm Reduct J
|
2011
|
0.92
|
|
50
|
Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8).
|
Qual Life Res
|
2007
|
0.91
|
|
51
|
Individual and structural factors associated with HIV status disclosure to main partner in Cameroon: ANRS 12-116 EVAL survey, 2006-2007.
|
J Acquir Immune Defic Syndr
|
2011
|
0.91
|
|
52
|
Multiple discriminations experienced by people living with HIV in France: results from the ANRS-Vespa2 study.
|
AIDS Care
|
2014
|
0.90
|
|
53
|
Unsafe sex with casual partners and quality of life among HIV-infected gay men: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA).
|
J Acquir Immune Defic Syndr
|
2006
|
0.89
|
|
54
|
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.
|
BMC Infect Dis
|
2010
|
0.89
|
|
55
|
Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention.
|
AIDS Care
|
2010
|
0.88
|
|
56
|
Sexual difficulties in people living with HIV in France--results from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA).
|
AIDS Behav
|
2008
|
0.87
|
|
57
|
Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods.
|
Expert Rev Anti Infect Ther
|
2013
|
0.87
|
|
58
|
Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial.
|
J Acquir Immune Defic Syndr
|
2013
|
0.87
|
|
59
|
The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination.
|
AIDS
|
2003
|
0.87
|
|
60
|
Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord.
|
AIDS
|
2014
|
0.87
|
|
61
|
Frequency and correlates of late presentation for HIV infection in France: older adults are a risk group - results from the ANRS-VESPA2 Study, France.
|
AIDS Care
|
2014
|
0.87
|
|
62
|
Desire for a child among HIV-infected women receiving antiretroviral therapy in Cameroon: results from the national survey EVAL (ANRS 12-116).
|
AIDS Care
|
2010
|
0.86
|
|
63
|
Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).
|
BMC Health Serv Res
|
2012
|
0.85
|
|
64
|
Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in Côte d'Ivoire: results from the TRIVACAN trial (ANRS 1269).
|
Trop Med Int Health
|
2010
|
0.85
|
|
65
|
Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon.
|
J Acquir Immune Defic Syndr
|
2015
|
0.85
|
|
66
|
Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians.
|
Curr Pharm Des
|
2014
|
0.84
|
|
67
|
Adding HCV treatment to HIV treatment in HIV-HCV coinfected patients: the impact on the different dimensions of fatigue and self-reported side effects.
|
J Pain Symptom Manage
|
2007
|
0.84
|
|
68
|
Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine.
|
AIDS Care
|
2010
|
0.84
|
|
69
|
Implementing operational research to scale-up access to antiretroviral therapy for HIV infection: lessons learned from the Cameroonian experience.
|
Curr Opin HIV AIDS
|
2011
|
0.84
|
|
70
|
Call for action to secure universal access to ART in developing countries.
|
Lancet
|
2010
|
0.84
|
|
71
|
Health-related quality of life and health locus of control beliefs among HIV-infected treated patients.
|
J Psychosom Res
|
2005
|
0.83
|
|
72
|
How do HIV-infected smokers react to cigarette price increases? Evidence from the APROCO-COPILOTE-ANRS CO8 Cohort.
|
Curr HIV Res
|
2009
|
0.83
|
|
73
|
Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial.
|
BMC Public Health
|
2012
|
0.82
|
|
74
|
Impact of HIV comprehensive care and treatment on serostatus disclosure among Cameroonian patients in rural district hospitals.
|
PLoS One
|
2013
|
0.82
|
|
75
|
Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys).
|
AIDS Care
|
2014
|
0.82
|
|
76
|
Visiting one's native country: the risks of nonadherence in HIV-infected sub-Saharan migrants--ANRS VIHVO study.
|
J Int Assoc Provid AIDS Care
|
2013
|
0.81
|
|
77
|
Has the employment status of people living with HIV changed since the early 2000s?
|
AIDS
|
2015
|
0.81
|
|
78
|
Incidence, medical and socio-behavioural predictors of psychiatric events in an 11-year follow-up of HIV-infected patients on antiretroviral therapy.
|
Antivir Ther
|
2012
|
0.81
|
|
79
|
Distributive sharing among HIV-HCV co-infected injecting drug users: the preventive role of trust in one's physician.
|
AIDS Care
|
2011
|
0.81
|
|
80
|
Low alcohol consumption as a predictor of higher CD4+ cell count in HIV-treated patients: a french paradox or a proxy of healthy behaviors? The ANRS APROCO-COPILOTE CO-08 cohort.
|
J Acquir Immune Defic Syndr
|
2014
|
0.81
|
|
81
|
Adherence as a predictor of sexual behaviors in people living with HIV/AIDS during the first year of antiretroviral therapy in rural Cameroon: data from Stratall ANRS 12110/ESTHER trial.
|
PLoS One
|
2012
|
0.81
|
|
82
|
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
|
Ther Drug Monit
|
2005
|
0.81
|
|
83
|
Susceptibility to transmitting HIV in patients initiating antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial).
|
PLoS One
|
2013
|
0.81
|
|
84
|
Adherence to and effectiveness of highly active antiretroviral treatment for HIV infection: assessing the bidirectional relationship.
|
Med Care
|
2012
|
0.80
|
|
85
|
Prevalence and predictors of deterioration of a trustful patient-provider relationship among HIV-infected persons treated with antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2008
|
0.80
|
|
86
|
Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).
|
Addiction
|
2013
|
0.80
|
|
87
|
Proximity to HIV is associated with a high rate of HIV testing among men who have sex with men living in Douala, Cameroon.
|
AIDS Care
|
2012
|
0.80
|
|
88
|
Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy.
|
BMJ Open
|
2012
|
0.79
|
|
89
|
Decentralization of access to antiretroviral therapy in Cameroon: correlates of HIV physicians' knowledge in HIV care.
|
Antivir Ther
|
2011
|
0.79
|
|
90
|
Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users: 7-year follow up.
|
AIDS
|
2004
|
0.79
|
|
91
|
Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the Stratall ANRS 12110/ESTHER trial in Cameroon.
|
Clin Infect Dis
|
2013
|
0.79
|
|
92
|
[Economic and socio-behavioural issues related to highly active antiretroviral therapies for HIV infection: the contribution of social science research].
|
Med Sci (Paris)
|
2003
|
0.78
|
|
93
|
Correlates of poor perceived health among individuals living with HIV and HBV chronic infections: a longitudinal assessment.
|
AIDS Care
|
2011
|
0.78
|
|
94
|
Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
|
J Antimicrob Chemother
|
2011
|
0.78
|
|
95
|
Coming out of the Nkuta: disclosure of sexual orientation associated with reduced risk behavior among MSM in Cameroon.
|
Arch Sex Behav
|
2012
|
0.78
|
|
96
|
Depressive symptoms and exposure to efavirenz in West African HIV-infected adults.
|
HIV Clin Trials
|
2009
|
0.78
|
|
97
|
HIV/AIDS: a long-term research agenda for social sciences.
|
AIDS Care
|
2008
|
0.78
|
|
98
|
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.
|
Antimicrob Agents Chemother
|
2003
|
0.78
|
|
99
|
Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART).
|
Drug Alcohol Depend
|
2008
|
0.78
|
|
100
|
Harm reduction and control of HIV in IDUs in France.
|
Lancet
|
2008
|
0.78
|
|
101
|
Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study.
|
Addiction
|
2010
|
0.78
|
|
102
|
Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort.
|
Antivir Ther
|
2015
|
0.77
|
|
103
|
Smoking motivations and quitting motivations among HIV-infected smokers.
|
Antivir Ther
|
2009
|
0.77
|
|
104
|
'Forced treatment interruptions' and risk of HIV resistance in countries adopting law enforcement against marginalized populations.
|
AIDS
|
2007
|
0.77
|
|
105
|
Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
|
Addiction
|
2011
|
0.77
|
|
106
|
Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients.
|
J Clin Gastroenterol
|
2008
|
0.77
|
|
107
|
Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study).
|
AIDS Care
|
2011
|
0.77
|
|
108
|
High viral loads among HIV-positive MSM attending gay venues: implications for HIV transmission.
|
J Acquir Immune Defic Syndr
|
2013
|
0.77
|
|
109
|
French HIV experts on early antiretroviral treatment for prevention: uncertainty and heterogeneity.
|
J Int Assoc Provid AIDS Care
|
2014
|
0.77
|
|
110
|
Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.
|
Expert Rev Gastroenterol Hepatol
|
2014
|
0.77
|
|
111
|
Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment.
|
J Urban Health
|
2004
|
0.76
|
|
112
|
Disclosure and religion among people living with HIV/AIDS in France.
|
AIDS Care
|
2008
|
0.76
|
|
113
|
Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.
|
Antivir Ther
|
2013
|
0.76
|
|
114
|
Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon -- data from the STRATALL ANRS 12110/ESTHER trial.
|
AIDS Care
|
2013
|
0.76
|
|
115
|
Time to combine intervention with prevention in countries where HIV is also driven by hazardous drinking: The journal publishes both invited and unsolicited letters.
|
Addiction
|
2012
|
0.76
|
|
116
|
Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13).
|
Hepatology
|
2012
|
0.76
|
|
117
|
Effect of anxiety symptoms on adherence to highly active antiretroviral therapy in HIV-infected women.
|
J Clin Psychiatry
|
2009
|
0.76
|
|
118
|
Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
|
HIV Clin Trials
|
2010
|
0.75
|
|
119
|
No variability across centers in adherence and response to HAART in French hospitals: results from the ANRS-EN12-VESPA study.
|
J Acquir Immune Defic Syndr
|
2009
|
0.75
|
|
120
|
The burden of HIV experience and care among MSM having an HIV-positive seroconcordant steady partner: a possible research hypothesis. Results from the French VESPA ANRS EN-12 study.
|
Sex Transm Infect
|
2011
|
0.75
|
|
121
|
Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions.
|
Subst Abuse Treat Prev Policy
|
2014
|
0.75
|
|
122
|
Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French National Survey).
|
J Acquir Immune Defic Syndr
|
2015
|
0.75
|
|
123
|
Minimal interference: A basis for selecting ART for prevention with positives.
|
AIDS Care
|
2013
|
0.75
|
|
124
|
AIDSImpact--more than a virus.
|
AIDS Care
|
2012
|
0.75
|
|
125
|
Do migrants overreport adherence to highly active antiretroviral therapy?: results from the French VESPA (ANRS-EN12) National Survey.
|
J Acquir Immune Defic Syndr
|
2006
|
0.75
|
|
126
|
Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).
|
Eur J Gastroenterol Hepatol
|
2017
|
0.75
|
|
127
|
Similar short-term efficacy of antiretroviral therapy in patients infected with HIV B and non-B subtype strains in france.
|
J Acquir Immune Defic Syndr
|
2011
|
0.75
|
|
128
|
Quality of life assessment in HIV clinical research in resource-limited settings: better late than never.
|
Trop Med Int Health
|
2010
|
0.75
|
|
129
|
[Mental health of HIV-positive women in France in the era of antiretroviral therapies: what differences between men and women? What is at stake?].
|
Med Sci (Paris)
|
2008
|
0.75
|
|
130
|
[Couple life, gender and HIV disease].
|
Med Sci (Paris)
|
2008
|
0.75
|
|
131
|
Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).
|
Expert Rev Gastroenterol Hepatol
|
2015
|
0.75
|
|
132
|
HIV-positive men who have sex with men: biography, diversity in lifestyles, common experience of living with HIV. ANRS-EN12 VESPA Study, 2003.
|
AIDS Care
|
2010
|
0.75
|
|
133
|
Costs and benefits of On-Demand HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men Analysis of the ANRS IPERGAY study with a one-year follow-up.
|
AIDS
|
2017
|
0.75
|
|
134
|
Prolonged viral suppression over a 12-year follow-up of HIV-infected patients: the persistent impact of adherence at 4 months after initiation of combined antiretroviral therapy in the ANRS CO8 APROCO-COPILOTE cohort.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
135
|
[Seropositive people infected through intravenous drug use: a persistent vulnerability].
|
Rev Prat
|
2005
|
0.75
|
|
136
|
Editorial: contexts and complexity - special considerations in HIV and social science.
|
AIDS Care
|
2008
|
0.75
|
|
137
|
Incidence and risk factors for recurrent sexually transmitted infections among men who have sex with men on HIV pre-exposure prophylaxis.
|
AIDS
|
2022
|
0.75
|
|
138
|
Is PrEP Needed for MSM in West Africa? HIV Incidence in a Prospective Multicountry Cohort.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
139
|
Is PrEP needed for MSM in West Africa? HIV incidence in a prospective multi-country cohort.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
140
|
Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines.
|
J Acquir Immune Defic Syndr
|
2010
|
0.75
|
|
141
|
Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
|
Eur J Gastroenterol Hepatol
|
2016
|
0.75
|
|
142
|
Choice of therapeutic strategies in the context of HIV infection: key role of patient-reported outcomes.
|
Expert Rev Anti Infect Ther
|
2012
|
0.75
|